Open call for evidence

The misuse and harms of gabapentin and pregabalin

Summary

Call for evidence to support ACMD's review of the misuse and harms of gabapentin and pregabalin.

This call for evidence closes at

Call for evidence description

The Advisory Council on the Misuse of Drugs (ACMD) is currently reviewing the evidence on the misuse and harms of pregabalin and gabapentin (gabapentinoids) in the United Kingdom.

This call for evidence will provide qualitative data to help the ACMD to:

  • inform the development of recommendations to government on how to best limit the harms posed by the potential misuse of gabapentinoids

  • assess whether the classification of gabapentin and pregabalin to Class C under the Misuse of Drugs Act 1971 has had the intended effect

The call is for any individual or organisation with knowledge or lived experience regarding the potential for harm caused by the misuse of pregabalin and gabapentin including:

  • healthcare professionals
  • researchers and academics
  • service providers

Responses can be submitted on a personal basis or as a representative of an organisation.

Documents

The misuse and harms of gabapentin and pregabalin: downloadable questions

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ways to respond

Updates to this page

Published 22 August 2025

Sign up for emails or print this page